Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

0
30


(Reuters) – Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co’s drug, Ruzurgi, for a rare neuromuscular disease.

Ruzurgi was approved last month for treating Lambert-Eaton myasthenic syndrome that affects about one in 100,000 people in the United States.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur

Our Standards:The Thomson Reuters Trust Principles.

LEAVE A REPLY

Please enter your comment!
Please enter your name here